We led a clinical and molecular characterization of a patient with mild mental delay and dysmorphic features initially referred for cytogenetic exploration of an azoospermia. We employed FISH and array CGH techniques for a better definition and refinement of a double chromosome aberration associating a 17p microdeletion with partial monosomy 21q due to 1:3 meiotic segregation of a maternal reciprocal translocation t(17;21)(p13.3;q21.2) revealed after banding analysis. Brain MRI depicted partial callosal and mild diffuse cerebral atrophies, but without expected signs of lissencephaly. The patient’s karyotype formula was: 45,XY,der(17)t(17;21)(p13.3;q21.2)mat,–21. FISH study confirmed these rearrangements and array CGH analysis estimated the loss sizes to at least 635 kb on chromosome 17 and to 15.6 Mb on chromosome 21. The absence of lissencephaly and major brain malformations often associated with 17p terminal deletions could be attributed to the retention of PAFAH1B1, YWHAE and CRK genes. Dysmorphic features, moderate mental impairment and minor brain malformations could result from the 21q monosomy and particularly the partial deletion of the APP-SOD1 region. Azoospermia should result from gamete apoptosis induced by a control mechanism triggered in response to chromosome imbalances. Our study provides an additional case for better understanding and delineating both 17p and 21q deletions.

Keywords:
Array CGH, Brain malformations, Mental retardation, Microdeletion 17pter→17p13.3, Monosomy 21pter→21q21.3
1.
Bruno DL, Anderlid BM, Lindstrand A, van Ravenswaaij-Arts C, Ganesamoorthy D et al: Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. J Med Genet 47:299–311 (2010).
2.
Cardoso C, Leventer RJ, Ward HL, Toyo-Oka K, Chung J, et al: Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. Am J Hum Genet 72:918–930 (2003).
3.
Chabchoub E, De Ravel T, Thoelen R, Vermeesch JR, Fryns JP, Van Esch H: Detection of an unusual 17p13.3 microdeletion by array comparative genomic hybridization in a patient with lissencephaly. Clin Genet 70:535–537 (2006).
4.
Chettouh Z, Croquette MF, Delobel B, Gilgenkrants S, Leonard C, et al: Molecular mapping of 21 features associated with partial monosomy: involvement of the APP-SOD1 region. Am J Hum Genet 57:62–71 (1995).
5.
Dobyns WB, Leventer RJ: Lissencephaly: the clinical and molecular genetic basis of diffuse malformations of neuronal migration, in Barth P (ed): Disorders of Neuronal Migration, pp 24–57 (Mac Keith, London 2003).
6.
Eden VH, Amanda JW, Kristin SP, Dobyns WB, Das S: Intragenic deletions and duplications of the LIS1 and DCX genes: a major disease-causing mechanism in lissencephaly and subcortical band heterotopias. Eu J Hum Genet 17:911–918 (2009).
7.
Frydman N, Romana S, Le Lorc’h M, Vekemans M, Frydman R, Tachdjian G: Assisting reproduction of infertile men carrying a Robertsonian translocation. Hum Reprod 16:2274–2277 (2001).
8.
Gijsbers AC, van Haeringen A, Bosch CA, Hansson K, Verschuren M, et al: A subtle familial translocation t(3;21)(p26.3;q22.3): an apparently healthy boy with a 3p deletion and 21q duplication. Cytogenet Genome Res 128:245–249 (2010).
9.
Kato M, Dobyns WB: Lissencephaly and the molecular basis of neuronal migration. Hum Mol Genet 12:89–96 (2003).
10.
Kerjan G, Gleeson JG: Genetic mechanisms underlying abnormal neuronal migration in classical lissencephaly. Trends Genet 23:623–629 (2007).
11.
Keren B, Bernardin C, Toutain A, Heron D, Fouquet B, et al: Pure proximal deletion of chromosome 21 and kyphosis. Eur J Med Genet 50:469–474 (2007).
12.
Lindstrand A, Malmgren H, Sahlén S, Schoumans J, Nordgren A, et al: Detailed molecular and clinical characterization of three patients with 21q deletions. Clin Genet 77:145–154 (2010).
13.
Lyle R, Be´na F, Gagos S, Gehrig C, Lopez G, et al: Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet 17:454–466 (2009).
14.
Martin CL, Waggoner DJ, Wong A, Uhrig S, Roseberry JA, et al: ‘Molecular rulers’ for calibrating phenotypic effects of telomere imbalance. J Med Genet 39:734–740 (2002).
15.
Mignon-Ravix C, Cacciagli P, El-Waly B, Moncla A, Milh M, et al: Deletion of YWHAE in a patient with periventricular heterotopias and pronounced corpus callosum hypoplasia. J Med Genet 47:132–136 (2010).
16.
Oegema R, de Klein A, Verkerk AJ, Schot R, Dumee B, et al: Distinctive phenotypic abnormalities associated with submicroscopic 21q22 deletion including DYRK1A. Mol Syndromol 1:113–120 (2010).
17.
Orti R, Mégarbane A, Maunoury C, Van Broeckhoven C, Sinet PM, Delabar JM: High-resolution physical mapping of a 6.7-Mb YAC contig spanning a region critical for the monosomy 21 phenotype in 21q21.3–q22.1. Genomics 43:25–33 (1997).
18.
Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM, Sloos W, et al: Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. J Med Genet 43:180–186 (2006).
19.
Rives N, Mousset-Siméon N, Sibert L, Duchesne V, Macé L, et al: Chromosome abnormalities of spermatozoa [French]. Gynecol Obstet Fertil 32:771–778 (2004).
20.
Schaffer LG, Slovak ML, Campbell LJ (eds): ISCN 2009: An International System for Human Cytogenetic Nomenclature (Basel, Karger 2009).
21.
Schiff M, Delahaye A, Andrieux J, Sanlaville D, Vincent-Delorme C, et al: Further delineation of the 17p13.3 microdeletion involving YWHAE but distal to PAFAH1B1: four additional patients. Eu J Med Genet 53:303–308 (2010).
22.
Sanlaville D, Lapierre JM, Coquin A, Turleau C, Vermeesch J, et al: Microarray CGH: principle and use for constitutional disorders [French]. Arch Pediatr 12:1515–1520 (2005).
23.
Toyo-oka K, Shionoya A, Gambello MJ, Cardoso C, Leventer R, et al: 14-3-3 epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. Nat Genet 34:274–285 (2003).
24.
Valero R, Marfany G, Gil-Benso R, Ibáñez MA, López-Pajares I, et al: Molecular characterisation of partial chromosome 21 aneuploidies by fluorescent PCR. J Med Genet 36:694–699 (1999).
25.
Van Assche E, Bonduelle M, Tournaye H, Joris H, Verheyen G, et al: Cytogenetics of infertile men. Hum Reprod 11 Suppl 4:141–124 (1996).
26.
Wakui K, Toyoda A, Kubota T, Hidaka E, Ishikawa M, et al: Familial 14-Mb deletion at 21q11.2-q21.3 and variable phenotypic expression. J Hum Genet 47:511–516 (2002).
27.
Yao G, Chen XN, Flores-Sarnat L, Barlow GM, Palka G, et al: Deletion of chromosome 21 disturbs human brain morphogenesis. Genet Med 8:1–7 (2006).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.